Canada’s PlantForm has signed an agreement with Brazil’s Bio-Manguinhos immunobiological technology institute within the Oswaldo Cruz Foundation (Fiocruz) biologics research and development organization to develop a biosimilar of Merck’s Keytruda (pembrolizumab) for the Brazilian market.
The deal also involves the PlantPraxis joint venture formed in 2014 by PlantForm and Brazil’s PharmaPraxis to develop, manufacture and commercialize biosimilars for the Brazilian market, using PlantForm’s proprietary manufacturing system